See how comprehensive, noninvasive solutions for assessing pre-transplant donor screening & HLA testing, and post transplant subclinical and acute rejection, infection and toxicity could benefit your transplant program.
Experience and Service You Can Trust
Viracor Eurofins was one of the first laboratories in the U.S. dedicated to serving the distinctive needs of transplant patients.
As a specialty lab partnering with approximately 60% of U.S. transplant programs, Viracor understands the complex diagnostic challenges that can occur, and your related testing needs pre and post transplantation.
When your solid organ transplant (SOT) patients face complications, you need accurate and rapid results to minimize infection and graft failure.
Every BMT/HSCT procedure comes with complications that can very quickly cascade into a life-threatening situation. Symptoms often mimic each other, making diagnosis and management complex. Viracor understands that early recognition and prompt intervention are critical for patients suspected of having an infection or complication. You can depend on Viracor for differential diagnostic testing with rapid turnaround time.
Powered by Transplant Genomics
The only blood test to rule out subclinical rejection in transplant patients with stable renal function, covered by CMS.
Introducing a donor-derived cell-free DNA assay that utilizes a liquid biopsy and provides healthcare professionals with actionable data — comparable to other dd-cfDNA assays on the market — for evaluating rejection in kidney transplant patients.
When rejection is not the underlying cause of symptoms, could it be an active BKV or other infection? Infectious disease investigative testing can be critical for treatment management.
Immunosuppressive drugs are essential to prevent rejection, but the risk of toxicity varies due to an individual patient's metabolism, absorption and drug interactions. Additionally, variability is observed in the pharmacokinetics of triazole antifungal drugs. By using drug level monitoring, the physician is able to individualize drug dosage to improve efficacy and reduce toxicity.
The chart to the right illustrates the intended use for our transplant rejection testing. Designed to offer both stable and dysfunctional organ transplant patients the critical noninvasive solutions they need, the proprietary TruGraf® and Viracor TRAC™ assays can help physicians determine which test to utilize by patient type.
TruGraf is intended for use in transplant patients with stable organ function as an alternative to surveillance biopsies.
TRAC is a donor-derived cell-free DNA test for evaluating organ rejection.
Immunological rejection presents one of the main obstacles to the long-term success of organ transplantation. Accurate, noninvasive laboratory assays are emerging as an alternative to biopsies for diagnosis of rejection. One of the most promising assays makes use of the proportion of donor-derived cell-free DNA (dd-cfDNA) as an indicator of organ damage, primarily due to rejection but also potentially due to infection or drug toxicity. Reviewing data published to date demonstrates that measurement of dd-cfDNA has broad clinical utility as a rejection biomarker.
We know that accelerated, clinically meaningful results are critical to transplant patient outcomes. This is why we’re committed to bringing you fast, accurate results that can help you counter infections and minimize graft failure:
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor is committed to helping medical professionals, transplant teams and reference labs get results faster, when it matters most.
We would be honored to be your diagnostic testing partner. For more information and to set up an account, please click on the button below.
Connect with us